-
-
-
-
-
-
-
Applied DNA Announces New Follow-On LineaDNA Order from Global IVD Manufacturer for Use in Cancer Diagnostic Application
-
-
-
-
-
-
-
Applied DNA to Resume Quarterly Investor Call Cadence Beginning with FQ3'25 Financial Results Report in Mid-August
-
-
-
-
-
-
-
Applied DNA's LineaRx Subsidiary Stands Ready to Support the Reshoring of Drug Development and Manufacturing with U.S.-Produced Synthetic DNA
-
-
-
-
-
-
-
Applied DNA Sciences (APDN) Announces 1-For-50 Reverse Stock Split Effective March 14, 2025
-
-
-
-
-
-
-
Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-Cell Therapy Produced from Linea DNA
-
-
-
-
-
-
-
Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement
-
-
-
-
-
-
-
Applied DNA Selected by LRQA for Isotopic Testing Pilot Project in Pakistan
-
412,928 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

